BioMarin Pharmaceutical Financial Ratios
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical ratio analysis
BioMarin Pharmaceutical earned a net margin of 10.8% in FY 2025, down from 15.0% a year earlier. Gross margin was 77.7% compared with a median of 78.9% over the prior 9 years. Return on equity reached 5.7%, meaning BioMarin Pharmaceutical generated 0.06 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.10, and the current ratio was 5.21. At the end of FY 2025, BMRN traded at 33.0 times earnings; across the 5 fiscal years shown, its year-end P/E ranged from 19.5 to 138.0, with a median of 33.0. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 33.03 | 30.24 | 110.83 | 137.99 | — | 19.49 | — | — | — | — |
| Price / sales | 3.54 | 4.45 | 7.49 | 9.15 | 8.75 | 8.52 | 8.83 | 10.34 | 11.84 | 12.31 |
| Price / book | 1.87 | 2.24 | 3.66 | 4.17 | 3.79 | 3.87 | 4.82 | 5.20 | 5.54 | 4.97 |
| Gross margin | 77.7% | 79.7% | 78.0% | 76.0% | 74.5% | 71.8% | 78.9% | 78.9% | 81.6% | 81.2% |
| Operating margin | 12.7% | 17.0% | 7.7% | 7.7% | -4.5% | -2.3% | -5.9% | -8.3% | -1.1% | -71.9% |
| Net margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 45.9% | -1.4% | -5.2% | -8.9% | -56.4% |
| Free cash flow margin | 22.5% | 17.1% | 2.6% | 2.6% | 11.3% | -1.6% | -5.7% | -8.3% | -15.8% | -33.7% |
| Return on equity (ROE) | 5.7% | 7.5% | 3.4% | 3.1% | -1.5% | 20.8% | -0.8% | -2.6% | -4.2% | -22.8% |
| Return on assets (ROA) | 4.6% | 6.1% | 2.5% | 2.2% | -1.1% | 14.6% | -0.5% | -1.7% | -2.5% | -15.7% |
| Debt / equity | 0.10 | — | — | — | — | — | — | — | — | — |
| Current ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.16 | 4.76 | 2.08 | 3.93 | 2.70 | 3.24 |
| Revenue growth | 12.9% | 18.0% | 15.4% | 13.5% | -0.8% | 9.2% | 14.3% | 13.5% | 17.6% | 25.5% |
| EPS growth | -18.6% | 154.0% | 16.0% | — | -107.8% | — | — | — | — | — |